Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

  • There is currently no data for MXCT

AIM Block Admission Return / Total Voting Rights

20 Feb 2020 18:18

RNS Number : 6728D
MaxCyte, Inc.
20 February 2020
 

SCHEDULE 6

AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS

 

Please ensure the entries on this return are typed

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From 17 November 2018 To 20 February 2020

 

d. Number and class of securities not issued under scheme

 

415,759 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

96,496 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

319,263 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional blocklisting application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

57,403,583 (51,444,847 MXCT.L and 5,958,736 MXCS.L)

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

 

Date

 

20 February 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCURRWRRNUUUAR
Date   Source Headline
4th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
4th Feb 20217:00 amRNSCORRECTION: MaxCyte Announces £40m Subscription
3rd Feb 20214:36 pmRNSMaxCyte Announces £40 million Subscription
3rd Feb 20214:35 pmRNSAppointment of Joint Corporate Broker
21st Jan 20212:49 pmRNSIncrease to Block Listing
20th Jan 20217:00 amRNSTrading Update
11th Jan 20217:00 amRNSMyeloid Therapeutics Clinical & Commercial License
23rd Dec 20207:00 amRNSTrading Update
9th Nov 20201:00 pmRNSCARMA Cell Therapies at SITC 2020
9th Nov 20207:00 amRNSPresentations at Upcoming Virtual IR Conferences
2nd Nov 20203:52 pmRNSResult of AGM
22nd Oct 20206:22 pmRNSDisclosure of Remuneration for Non-Audit Services
14th Oct 20207:00 amRNSNotification of AGM and Audit Declaration
13th Oct 20207:00 amRNSMaxCyte announces leadership appointments
1st Oct 20207:00 amRNSDirector/PDMR Shareholding
21st Sep 20207:00 amRNSResults for the Six Months ended 30 June 2020
10th Sep 20201:42 pmRNSGrant of options
10th Sep 20207:00 amRNSHC Wainright & Co Virtual Conference Presentation
9th Sep 20207:00 amRNSAppointment of Amanda L. Murphy as CFO
2nd Sep 20202:57 pmRNSHolding(s) in Company
2nd Sep 20207:00 amRNSNotice of Half Year Results
18th Aug 20207:00 amRNSExpansion of CARMA’s Phase I Trial of MCY-M11
14th Aug 20207:00 amRNSHolding(s) in Company
16th Jul 20206:04 pmRNSDirector Dealings and Issue of Equity
15th Jul 20207:00 amRNSTrading Update
8th Jul 20207:00 amRNSAPEIRON Biologics Clinical and Commercial License
1st Jul 20207:00 amRNSBlock Listing Return & TVR
2nd Jun 20205:54 pmRNSHolding(s) in Company
28th May 20203:34 pmRNSHolding(s) in Company
26th May 20205:49 pmRNSHolding(s) in Company
26th May 20204:22 pmRNSHolding(s) in Company
26th May 20203:45 pmRNSHoldings in Company
21st May 20201:50 pmRNSResult of Special Meeting and Issue of Equity
14th May 20207:00 amRNSPoster Presentation on MCY-M11 at ASCO 2020
7th May 20207:00 amRNSLicense Agreement with Caribou Biosciences
1st May 20207:00 amRNSResult of Offering
30th Apr 20205:39 pmRNSProposed Offering to raise up to £25.1 million
21st Apr 20207:00 amRNSFinal Results for Year Ended 31 December 2019
9th Apr 20207:00 amRNSBusiness Update Related to COVID-19 Pandemic
24th Mar 20207:00 amRNSLicense Agreement with Allogene Therapeutics
21st Feb 20207:00 amRNSConsolidation of Trading Lines
20th Feb 20206:18 pmRNSAIM Block Admission Return / Total Voting Rights
5th Feb 20207:00 amRNSMaxCyte to Present at BIO CEO & Investor Conf
24th Jan 20204:31 pmRNSGrant Of Options
22nd Jan 20205:15 pmRNSHolding(s) in Company
22nd Jan 20205:11 pmRNSHolding(s) in Company
22nd Jan 20205:08 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSTrading Update
19th Dec 20197:00 amRNSNew Executive Vice President and Trial Update
16th Dec 20195:25 pmRNSDirector/PCA transaction initial notification

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.